380 related articles for article (PubMed ID: 25596270)
1. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
2. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
5. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
6. Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J; Mizutani S; Shimura Y; Maegawa S; Nagoshi H; Chinen Y; Tatekawa S; Tsukamoto T; Mizuno Y; Yamamoto-Sugitani M; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Ann Hematol; 2015 Apr; 94(4):687-9. PubMed ID: 25209844
[No Abstract] [Full Text] [Related]
7. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Moore S; Atwal S; Sachchithanantham S; Streetly M; Khan I; Percy L; Narat S; D'Sa S; Rabin N; Johnston R; Schey S; Yong K
Eur J Haematol; 2013 May; 90(5):420-5. PubMed ID: 23294279
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Scheid C; Sonneveld P; Schmidt-Wolf IG; van der Holt B; el Jarari L; Bertsch U; Salwender H; Zweegman S; Blau IW; Vellenga E; Weisel K; Pfreundschuh M; Jie KS; Neben K; van de Velde H; Duehrsen U; Schaafsma MR; Lindemann W; Kersten MJ; Peter N; Hänel M; Croockewit S; Martin H; Wittebol S; Bos GM; van Marwijk-Kooy M; Wijermans P; Goldschmidt H; Lokhorst HM
Haematologica; 2014 Jan; 99(1):148-54. PubMed ID: 23996482
[TBL] [Abstract][Full Text] [Related]
9. RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Smith D; Armenteros E; Percy L; Kumar M; Lach A; Herledan G; Stubbs M; Downward J; Yong K
Br J Haematol; 2015 Jun; 169(6):905-8. PubMed ID: 25580780
[No Abstract] [Full Text] [Related]
10. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
11. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
12. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):159-61. PubMed ID: 23084405
[No Abstract] [Full Text] [Related]
14. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Neuwirth R; Boral AL; Esseltine DL; Anderson KC
Leukemia; 2008 Apr; 22(4):842-9. PubMed ID: 18200040
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
17. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
19. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
Malani AK; Gupta V; Rangineni R
Acta Haematol; 2006; 116(4):255-8. PubMed ID: 17119326
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Cibeira MT; Zhuang SH; Harousseau JL; Orlowski RZ;
Clin Lymphoma Myeloma; 2008 Dec; 8(6):352-5. PubMed ID: 19064400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
